Missouri is currently home to 1899 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450
Recruiting
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Research Site, Columbia, Missouri
Conditions: Viral Lung Infection and Acute Respiratory Failure
Register for Updates
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
NCT05595460
Recruiting
This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Research Facility, Saint Louis, Missouri
Conditions: SCLC,Extensive Stage
Register for Updates
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646
Recruiting
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an... Read More
Gender:
ALL
Ages:
Between 12 years and 80 years
Trial Updated:
08/07/2025
Locations: Children's Mercy Research Institute, Kansas City, Missouri
Conditions: FSGS
Register for Updates
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
NCT05102019
Recruiting
To demonstrate the safety and effectiveness of the Shockwave Reducer for treatment of patients with refractory angina pectoris treated with maximally tolerated guideline-directed medical therapy who demonstrate objective evidence of reversible myocardial ischemia in the distribution of the left coronary artery and who are deemed unsuitable for revascularization. A non-randomized single-arm registry will further assess the safety and effectiveness of the Shockwave Reducer in selected subjects wit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Saint Luke's Hospital, Kansas City, Missouri
Conditions: Refractory Angina
Register for Updates
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
NCT04609046
Recruiting
This phase I trial tests the safety, side effects, best dose and effectiveness of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS) lymphoma. Lenalidomide may stop or slow primary CNS lymphoma by blocking the growth of new blood vessels necessary for tumor growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the abil... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri
Conditions: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
Register for Updates
An Internet-based Program to Help Cancer Survivors Manage Pain
NCT04462302
Recruiting
To determine whether an Internet-based pain coping skills program plus enhanced usual care, compared to enhanced usual care alone, yields significant improvements in the co-primary outcomes of pain severity (as measured by the Brief Pain Inventory (BPI)) and pain interference (also measured by the BPI) from baseline to the post-intervention assessment for cancer survivors with persistent pain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Central Care Cancer Center - Bolivar, Bolivar, Missouri
Conditions: Cancer
Register for Updates
Transvaginal Ultrasound and Photoacoustic Imaging of Ovary
NCT04178018
Recruiting
This study is being conducted to validate if photoacoustic imaging potentially reduces benign surgeries without compromising cancer detection sensitivity. The study will also explore whether using the photoacoustic imaging/ultrasound technique has any potential with early ovarian cancer detection in a group of high risk patients.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Ovary; Anomaly
Register for Updates
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
NCT03266653
Recruiting
Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Gender:
ALL
Ages:
Between 1 month and 79 years
Trial Updated:
08/07/2025
Locations: Washington University, Saint Louis, Missouri
Conditions: Epstein-Barr Virus Infections, Primary Immune Deficiency Disorder
Register for Updates
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
NCT03266640
Recruiting
CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory cytomegalovirus (CMV) infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Gender:
ALL
Ages:
Between 1 month and 79 years
Trial Updated:
08/07/2025
Locations: Washington University, Saint Louis, Missouri
Conditions: Cytomegalovirus Infections, Primary Immune Deficiency Disorder
Register for Updates
Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
NCT03266627
Recruiting
Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents and young adults with refractory ADV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Gender:
ALL
Ages:
Between 1 month and 79 years
Trial Updated:
08/07/2025
Locations: Washington University, Saint Louis, Missouri
Conditions: Adenovirus, Primary Immune Deficiency Disorder
Register for Updates
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
NCT03075696
Recruiting
This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), glofitamab, administered by intravenous (IV) infusion as a single agent and in combination with obinutuzumab, following pre-treatment with a one-time, fixed dose of obinutuzumab. This entry-into-human (EIH) study is divided in 3 parts: dose escalation (Parts I and II) and dose expansion (Part III). Single-partic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Washington University, Saint Louis, Missouri
Conditions: Non-Hodgkin's Lymphoma
Register for Updates
Fabry Disease Registry & Pregnancy Sub-registry
NCT00196742
Recruiting
The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The primary objectives of the Registry are: * To enhance the understanding of the variability, progression, and natural history of F... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/07/2025
Locations: University of Missouri Health System Department of Genetics- Site Number : 840031, Columibia, Missouri
Conditions: Fabry Disease
Register for Updates